-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Transfer from: Corporate Announcement Shell Finance and Economics: No worries
On September 1, Guangdong Dongyang Sunshine Technology Holdings Co.
The announcement shows that Guangdong Dongyang Sunshine Technology Holdings Co.
After preliminary research and calculation, it is expected that this transaction may constitute a major asset reorganization and related party transaction
Through this transaction, Dongyang Sunshine stated that since the company's resource advantages such as talents, technology and channels are mainly concentrated in related fields such as new electronic materials, the future investment of a large amount of resources into Dongyang Sun Pharmaceutical’s transformation and transformation is not conducive to giving full play to its comparative advantages.
From 2017 to 2019, the performance of Dongyang Sun Pharmaceuticals increased year by year, with revenues of 1.
In 2020, the outbreak of the new crown epidemic is superimposed on the peak season of influenza, and terminal hospitals have more stocks of the core product oseltamivir phosphate (trade name: Kewei) of Dongyang Pharmaceutical
The above-mentioned influence continued into the first half of this year.
East Sunshine believes that due to the continuing impact of the epidemic, the business environment of East Sunshine Pharmaceuticals has undergone major changes, faces greater pressure for change, and there are greater uncertainties in future performance
Dongyang Pharmaceutical, which was once considered to help improve its performance, was abandoned by the "owner".
Are the multiple retreats of Dongyang Sun Medicine effective?
Dongyang Sun Pharmaceutical is a subsidiary of Dongyang Sunshine Holdings, and Dongyang Sunshine holds 53.
Dongyang Sun Pharmaceutical products cover the field of antiviral, endocrine, cardiovascular and other disease treatments.
Today, Kewei is facing the "encirclement and suppression" of other competitors
In fact, Dongyang Sun Pharmaceutical has long been aware of the crisis of over-reliance on single products.
At the same time, Dongyang Pharmaceutical has a number of new drugs under development in the field of antiviral and diabetes, including the new anti-hepatitis C drug vorarivir, second and third generation insulin, small molecule class 1 new drug pyroglutamate rongglitazone and biological The analogue liraglutide, and a number of generic drugs that are deemed to have passed the consistency evaluation when transferred from abroad to China, the therapeutic areas cover multiple therapeutic areas such as diabetes, digestive system diseases and central nervous system diseases
Although Dongyang Sun Pharmaceuticals has a rich and diverse product reserve, whether it can effectively cope with operating risks and external market risks can only be known after the industrialization of related products
